



#8/C

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

ZAUDERER *et al.*

Appl. No. 09/824,787

Filed: April 4, 2001

For: **Gene Differentially Expressed in
Breast and Bladder Cancer, and
Encoded Polypeptides**

Confirmation No. 2970

Art Unit: ~~1645~~ 1642Examiner: *To be assigned*

Atty. Docket: 1821.0040001/EKS/TJS

**Amendment and Submission of Substitute Sequence Listing
Under 37 C.F.R. § 1.825(a)**Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with 37 C.F.R. § 1.825(a), Applicants submit substitute sheets to amend the paper copy of the Sequence Listing.

In the Specification:

Please cancel the existing Sequence Listing for the above-identified application, replace it with the substitute Sequence Listing appended hereto, and insert the same at the end of the application.

Remarks

Pursuant to the Notice of Incomplete Reply (Nonprovisional) mailed October 3, 2001, Applicants' hereby submit a substitute Sequence Listing to correct errors in the


previously filed submission. It is not believed that the changes made in the sequence listing include new matter.

In accordance with 37 C.F.R. § 1.825(b), the paper copy of the Sequence Listing and the computer readable copy of the Sequence Listing submitted herewith are the same.

It is respectfully believed this application is now in condition for allowance. Early notice to this effect is earnestly solicited.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Timothy J. Shea, Jr.
Attorney for Applicants
Registration No. 41,306

Date: 10/17/01

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600